Introduction: Vaccination of childrenhasexperienced delays due to
paucity of information regarding safety, effectiveness, immunogenicity, and
reactogenicity. Age wise approval prioritized 12-17
years and later 5-11 years. Those below 5
years possess na?ve immunity and not considered. In Lake Region Economic Bloc
children aged 12-17 variably received 1, 2,
and 3 doses of vaccine. This analysis looks into effectiveness of the doses
administered. Method: Data providers from 84 LREB facilities submitted
patients’ vaccination data to Power BI supported dashboard between June 24,
2021 and July 30, 2022. Data of 12-17 years oldwas mined, analyzed and
visualized. Sample sizes considered for analysis were 0 dose, n=8132; 1 dose, n=271; 2
doses, n=
References
[1]
Hause, A.M., Baggs, J., Marquez, P., Myers, T.R., Gee, J., Su, J.R., Shay, D.K., et al. (2021) COVID-19 Vaccine Safety in Children 5-11 Years—United States, November 3-December 19, 2021. Weekly, 70, 1755-1760.
[2]
Govender, K., Nyamaruze, P., McKerrow, N., Meyer-Weitz, A. and Cowden, R. (2022) COVID-19 Vaccines for Children and Adolescents in Africa: Aligning Our Priorities to Situational Realities. BMJ Global Health, 7, e007839. https://doi.org/10.1136/bmjgh-2021-007839
[3]
Terliesner, N., Unterwalder, N., Cormann, V., Edelmann, A., Knaust, A., Rosenfeld, L., Gratopp, A., Ringe, H., Martin, L., von Bernuth, H., Mall, M.A. and Kallinich, T, (2022) Viral Infections in Hospitalized Children in Germany during the COVID-19 Pandemic: Association with Non-Pharmaceutical Interventions. Frontiers in Pediatrics, 10, Article 935483. https://doi.org/10.3389/fped.2022.935483
[4]
Plotkin, S.A. and Levy, O. (2021) Considering Mandatory Vaccination of Children for COVID-19. Pediatrics, 147, e2021050531. https://doi.org/10.1542/peds.2021-050531
[5]
Zimmermann, P., Pittet, L.F., Finn, A., Pollard, A. and Curtis, N. (2022) Should Children Be Vaccinated against COVID-19. Archives of Disease in Childhood, 107, e1-e8. https://doi.org/10.1136/archdischild-2021-323040
[6]
Walter, E.B., Talaat, K.R., Sabharwal, C., Gurtman, A., Lockhart, S., Paulsen, G.C., Barnett, E.D., Muñoz, F.M., Maldonado, Y., Pahud, B.A., Domachowske, J.B., Simõeset, E.A.F., et al. (2022) Evaluation of COVID-19 Vaccines in Children 5 to 111 years of Age. The New England Journal of Medicine, 386, 35-46.
[7]
Creech, C.B., Anderson, E., Berthaud, V., Yildirim, I., et al. (2021) Evaluation of mRNA-1273 COVID-19 Vaccine in Children 6 to 11 Years of Age. The New England Journal of Medicine, 386, 2011-2023. https://doi.org/10.1056/NEJMoa2203315
[8]
Dionne, A., Sperotto, F., Chamberlain, S., Baker, A.L., Powell, A.J., Prakash, A., Castellanos, D.A., Saleeb, S., Fde Ferranti, S.D., Newburger, J.W. and Friedman, K.G. (2021) Association of Myocarditis with BNT162b2 Messenger RNA COVID-19 Vaccine in a Case Series of Children. JAMA Cardiology, 6, 1446-1450. https://doi.org/10.1001/jamacardio.2021.3471
[9]
World Health Organization (2021) Vaccines Work Is a Digital Platform Hosted by Gavi, the Vaccine Alliance Covering News, Features and Explainers from Every Corner of glObal Health and Immunisation. https://www.gavi.org/vaccineswork/about
[10]
The United Nations International Children’s Emergency Fund (2021) Child Mortality and COVID-19. https://data.unicef.org/topic/child-survival/covid-19/
[11]
Sachs, J.D., Karim, S.S.A., Aknin, L., Allen, J., Brosbøl, K., Colombo, F., Barron, G.C., Espinosa, M.F., Gaspar, V., Gaviria, A., Haines, A., Hotez, P.J., Koundouri, P., Bascuñán, F.L., Lee, J.K., Pate, M.A., Ramos, G., Reddy, K.S., Serageldin, I., Thwaites, J., Vike-Freiberga, V., Wang, C., Were, M.K., Xue, L., Bahadur, C., Bottazzi, M.E., Bullen, C., Laryea-Adjei, G., et al. (2022) Commission on Lessons for the Future from the COVID-19 Pandemic. The Lancet, 400, 1224-1280. https://doi.org/10.1016/S0140-6736(22)01585-9
[12]
Rodriguez Velásquez, S., Jacques, L., Dalal, J., Sestito, P., Habibi, Z., Venkatasubramanian, A., Nguimbis, B., Mesa, S.B., Chimbetete, C., Keiser, O., Impouma, B., Mboussou, F., William, G.S., Ngoy, N., Talisuna, A., Gueye, A.S., Hofer, C.B. and Cabore, J.W. (2021) The Toll of COVID-19 on African Children: A Descriptive Analysis of COVID-19 Related Morbidity and Mortality among the Pediatric Population of Sub-Saharan Africa. medRxiv. https://doi.org/10.1101/2021.07.02.21259857
[13]
Ministry of Health (2022) The First COVID-19 Case in Kenya. https://www.health.go.ke/wp-content/uploads/2022/11/SITREP-971-13-November-2022.pdf
[14]
Lake Region Economic Bloc (year) Lake Region Economic. COVID-Dx Digital Data Platform. https://lreb.or.ke/
[15]
Chemaitelly, H., AlMukdad, S., Ayoub, H.H., Altarawneh, H.N., Coyle, P., Tang, P., Yassine, H.M., Al-Khatib, H.A., Smatti, M.K., Hasan, M.R., Al-Kanaani, Z., Al-Kuwari, E., Jeremijenko, A., Kaleecka, A.H., Latif, A.N., Shaik, R.M., et al. (2022) COVID-19 Vaccine Protection among Children and Adolescents in Qatar. The New England Journal of Medicine, 387, 1865-1876. https://doi.org/10.1056/NEJMoa2210058
[16]
Liu, B., Gidding, H., Stepien, S., Cretikos, M. and Macartny, K. (2022) Relative Effectiveness of COVID-19 Vaccination with 3 Compared to 2 Doses against SARS-CoV-2 B.1.1.529 (Omicron) among an Australian Population with Low Prior Rates of SARS-CoV-2 Infection. Vaccine, 40, 6288-6294. https://doi.org/10.1016/j.vaccine.2022.09.029
[17]
Corves, C., Izurieta, H.S., Smith, J., Smith, G.M., Powell, E.I., Balajee, A. and Ryder, K.M. (2022) Relative Effectiveness of Booster vs. 2-Dose mRNA COVID-19 Vaccination in the Veterans Health Administration: Self-Controlled Risk Interval Analysis. Vaccine, 40, 4742-4747. https://doi.org/10.1016/j.vaccine.2022.06.047
[18]
Opel, D.J., Diekema, D.S. and Ross, L.F. (2021) Should We Mandate a COVID-19 Vaccine for Children? JAMA Pediatrics, 175, 125-126. https://doi.org/10.1001/jamapediatrics.2020.3019
